Research · Sep 3, 2026
[AXSM] Axsome Therapeutics Thesis 2026: Auvelity Depression Launch Drives Symbravo Migraine Pipeline
Axsome Therapeutics, Inc. (NASDAQ: AXSM) FY2025 revenue ~$575-625M (+90-110%) with adj. EPS ~-$1.95 to -$2.30 (continued opex investment + commercial scale-up loss) reflecting continued post-2024 ~$430-475M aggregate Auvelity (AXS-05; major depressive disorder) revenue (~75%+ aggregate revenue mix) + selected continued post-2024 ~$130-145M aggregate Sunosi (solriamfetol; excessive daytime sleepiness) revenue (~22-23% aggregate revenue mix) + selected continued post-2024 ~$5-15M aggregate Symbravo (AXS-07; migraine acute) initial launch revenue (~1-3% aggregate revenue mix) under continued Founder + CEO Herriot Tabuteau, MD since 2012 (~13-year tenure as Axsome Founder + CEO). US specialty CNS biopharmaceutical company. Founded January 2012 by Founder + CEO Herriot Tabuteau, MD in New York City (~13-year heritage); selected post-2015 NASDAQ IPO; selected post-August 2022 FDA approval (Auvelity for MDD); selected post-January 2025 FDA approval (Symbravo for migraine acute). Headquartered in New York City; ~700-800+ employees globally with ~$575-625M revenue. One primary business segment: Specialty CNS Pharmaceutical (~100% ~$575-625M). Geographic mix: US ~100%. Auvelity depression launch: ~$430-475M Auvelity revenue (~75%+ revenue mix); ~+90-110% Auvelity TRx growth; ~30,000-40,000 prescribers; ~17M+ aggregate US MDD prevalence; selected post-August 2022 FDA approval. Symbravo migraine launch + Phase 3 pipeline: Symbravo (AXS-07; migraine acute) selected post-January 2025 FDA approval + selected post-Q2 2025 launch; selected post-2024 AXS-12 (narcolepsy) + AXS-14 (fibromyalgia) + AXS-05 Alzheimer's agitation Phase 3 readouts. Founder + CEO Herriot Tabuteau, MD since 2012 (~13-year tenure); CFO Lori Englebert. Capital position: ~$330-400M aggregate cash + investments balance; ~$175-225M aggregate quarterly cash burn; selected projected post-2026 cash flow break-even; ~46-48M diluted shares; no dividend (~$0 dividend track post-2015 IPO); selected ~$80M+ aggregate Founder ownership concentration. FY2026 thesis: Auvelity depression launch acceleration + Symbravo migraine launch + selected Phase 3 readouts (AXS-12 narcolepsy + AXS-14 fibromyalgia + AXS-05 Alzheimer's agitation) + selected projected post-2026 cash flow break-even + Founder + CEO Herriot Tabuteau (~13-year tenure). Risks: AbbVie + Pfizer + Eli Lilly Emgality + GLP-1/Spravato + Lilly Emrxa competition, Phase 3 readout binary risk, payer access + Medicare Part D, sustained cash burn delay break-even.